Mission & history

PHAXIAM, a merger between two French biotech companies

Our mission

PHAXIAM is a clinical-stage biopharmaceutical company developing innovative bacteriophage-based therapies to fight antimicrobial resistance (AMR).


PHAXIAM relies on an innovative approach based on the use of phages, natural bacteria-killing viruses, with a targeted approach, to fight resistant bacterial infections.


PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, responsible for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.


PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Our history

PHAXIAM is the result of the merger, in June 2023, of two well-established French biotech companies: ERYTECH and PHERECYDES.


Creation of PHERECYDES, a French company specialized in phage therapy to treat resistant bacterial infections. The company is addressing a major public health challenge, and is already benefiting from promising initial clinical results and clinical development opportunities.

June 2023

Approved in June 2023, the combination between ERYTECH and PHERECYDES capitalizes on the complementary expertise and resources of the two companies to accelerate the development of a diversified phage therapy portfolio, aimed at combating antimicrobial resistance (AMR), a global health issue.


Creation of ERYTECH, in Lyon, a clinical-stage biopharmaceutical company focused, until 2022, on the development of innovative therapies based on red blood cells to fight cancers and orphan diseases.

February 2023

Following the discontinuation of its Phase 3 trial in pancreatic cancer, ERYTECH decided to open a new chapter in its history by investing in a therapeutic area involving global health issues: bacterial resistance to antibiotics. The planned merger with PHERECYDES, announced in February 2023, is the result of an in-depth selection process lasting over a year.

Interested in joining PHAXIAM ?

See our job offers or send us your unsolicited application.

Career opportunities

our team

Journalist, investor, healthcare professional, partner or candidate... if you have any questions about PHAXIAM, please do not hesitate to contact our teams.

Contact us